Cargando…
The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism
Uveal melanoma (UM) is the most common primary cancer of the eye in adults and progresses to metastatic disease predominantly of the liver in ∼50% of patients. In these cases, life expectancy averages just 9 months due to the lack of effective treatment options. The Toll-like receptor 5 (TLR5) agoni...
Autores principales: | Yang, Hua, Brackett, Craig M., Morales-Tirado, Vanessa Marie, Li, Zezhong, Zhang, Qing, Wilson, Matthew W., Benjamin, Camille, Harris, Wayne, Waller, Edmund K., Gudkov, Andrei V., Burdelya, Lyudmila G., Grossniklaus, Hans E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823082/ https://www.ncbi.nlm.nih.gov/pubmed/26655090 http://dx.doi.org/10.18632/oncotarget.6500 |
Ejemplares similares
-
Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice
por: Kojouharov, Bojidar M., et al.
Publicado: (2014) -
TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects
por: Haderski, Gary J., et al.
Publicado: (2020) -
The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates
por: Krivokrysenko, Vadim I., et al.
Publicado: (2015) -
A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications
por: Mett, Vadim, et al.
Publicado: (2021) -
A Flagellin-Derived Toll-Like Receptor 5 Agonist Stimulates Cytotoxic Lymphocyte-Mediated Tumor Immunity
por: Leigh, Nicholas D., et al.
Publicado: (2014)